{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:29:43Z","timestamp":1794738583027,"version":"4.9.1"},"reference-count":45,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Identifying factors influencing peak inspiratory flow (PIF) is essential for aerosol drug delivery in stable patients with chronic obstructive pulmonary disease. While a minimum PIF for dry powder inhalers (DPIs) is established, acute bronchodilator (BD) effects on PIF remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      An inspiratory flow meter (In-Check\u2122 DIAL) was used to measure PIF in stable patients during a 24-week observational cross-sectional study. Additionally, bronchodilator responsiveness (BDR) was determined using the In-Check DIAL device and spirometry. Patients received four puffs of albuterol, and pre- and post-BD PIF, forced expiratory volume in one second (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), and forced vital capacity were measured. Sixty-three patients completed acute BDR data collection from July 31, 2019, to November 9, 2021. Primary endpoints were pre- and post-BD spirometry and PIF. Statistical analyses included PIF correlations with FEV\n                      <jats:sub>1<\/jats:sub>\n                      . BD change was assessed according to inhaler resistance and sex (subgroup analysis).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Median patient age was 64.8 years, 85.7% were non-Hispanic White, and 57.1% were female. The median increase in absolute PIF (In-Check DIAL) was 5.0\u2009L\/min, and the % PIF change was 8.9%. With albuterol, 57.1% experienced a PIF BD change &gt;5.0%, whereas 49.2% experienced a change &gt;10.0%. Similarly, 55.6% experienced an FEV\n                      <jats:sub>1<\/jats:sub>\n                      BD change &gt;5.0% and 28.6% had a &gt;10.0% FEV\n                      <jats:sub>1<\/jats:sub>\n                      BD change with albuterol. PIF was weakly correlated with FEV\n                      <jats:sub>1<\/jats:sub>\n                      BD change (absolute; % PIF;\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.28 [\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.02];\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2009=\u20090.21 [\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.11]). Pre- and post-BD median PIF were 75.5 and 83.5\u2009L\/min for low-to-medium\u2013resistance DPI and 45.0 and 52.0\u2009L\/min for high-resistance, respectively. The median increases in pre- and post-BD PIF were 9.0\u2009L\/min in males and 4.5\u2009L\/min in females. In contrast to when using the In-Check DIAL device, we observed no consistent bronchodilatory effects on PIF measured by spirometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Using the In-Check DIAL device, \u223c50% of patients experienced &gt;10% PIF increase after acute BD, potentially enhancing medication lung deposition. Further research is required to understand PIF's impact on medication delivery.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      Identifier: NCT04168775\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jamp.2023.0045","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T08:28:56Z","timestamp":1717057736000},"page":"171-179","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Changes in Peak Inspiratory Flow After Acute Bronchodilation: An Observational Study of Patients with Stable Chronic Obstructive Pulmonary Disease"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-2487","authenticated-orcid":false,"given":"Roy A.","family":"Pleasants","sequence":"first","affiliation":[{"name":"Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA."},{"name":"Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley G.","family":"Henderson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bayer","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Bradley","family":"Drummond","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"GOLD. Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease (2023 report). Available from: https:\/\/goldcopd.org\/wp-content\/uploads\/2023\/03\/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf [Last accessed: March8 2023]."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S174371"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201702-156PS"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00166410"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.94.07010069"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2017.1416"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201611-903OC"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1495867"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221107312"},{"issue":"3","key":"e_1_3_6_11_2","first-page":"217","article-title":"Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation","volume":"4","author":"Sharma G","year":"2017","unstructured":"Sharma G, , Mahler DA, , Mayorga VM, et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis, 2017; 4(3):217\u2013224; doi: 10.15326\/jcopdf.4.3.2017.0183","journal-title":"Chronic Obstr Pulm Dis"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10092105"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.61.1.11"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.3.308"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1371-x"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14845"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.03.049"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105857"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S220164"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S319511"},{"key":"e_1_3_6_22_2","unstructured":"Spirometry. Vitalograph Pneumotrac powered by comPAS2\u2014the pinnacle of spirometry testing. Available from: www.morgansci.com\/products\/spirometry\/ [Last accessed: July17 2023]."},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035205"},{"issue":"3","key":"e_1_3_6_24_2","first-page":"332","article-title":"Flow and volume response to bronchodilator in patients with COPD","volume":"89","author":"Vigna M","year":"2018","unstructured":"Vigna M, , Aiello M, , Bertorelli G, et al. Flow and volume response to bronchodilator in patients with COPD. Acta Biomed, 2018; 89(3):332\u2013336; doi: 10.23750\/abm.v89i3.5631","journal-title":"Acta Biomed"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00129607"},{"issue":"3","key":"e_1_3_6_26_2","first-page":"427","article-title":"High prevalence of suboptimal peak inspiratory flow in hospitalized patients with COPD: A real-world study","volume":"9","author":"Mahler DA","year":"2022","unstructured":"Mahler DA, , Demirel S, , Hollander R, et al. High prevalence of suboptimal peak inspiratory flow in hospitalized patients with COPD: A real-world study. Chronic Obstr Pulm Dis, 2022; 9(3):427\u2013438; doi: 10.15326\/jcopdf.2022.0291","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"4","key":"e_1_3_6_27_2","first-page":"321","article-title":"Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate","volume":"6","author":"Mahler DA","year":"2019","unstructured":"Mahler DA, , Ohar JA, , Barnes CN, et al. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstr Pulm Dis, 2019; 6(4):321\u2013331; doi: 10.15326\/jcopdf.6.4.2019.0137","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"3","key":"e_1_3_6_28_2","first-page":"246","article-title":"Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD","volume":"6","author":"Duarte AG","year":"2019","unstructured":"Duarte AG, , Tung L, , Zhang W, et al. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. Chronic Obstr Pulm Dis, 2019; 6(3):246\u2013255; doi: 10.15326\/jcopdf.6.3.2018.0163","journal-title":"Chronic Obstr Pulm Dis"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105298"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2001.1411"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.11.017"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.70.10.866"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.08.004"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-496"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(59)90247-5"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.3.8630581"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2012.0987"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S11474"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00024807"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2003.1289"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2008.04.005"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2013.1038"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123949"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-021-00167-4"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40521-023-00328-7"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.11.037"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2023.0045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2023.0045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2023.0045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:11:36Z","timestamp":1777644696000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2023.0045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8,1]]}},"alternative-id":["10.1089\/jamp.2023.0045"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2023.0045","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}